In March 2017, Capnia, Inc. acquired Essentialis, Inc. and in May 2017 changed its name to Soleno Therapeutics, Inc., which is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases.
Our core commitment is to provide safe and effective products that make a difference by providing innovative solutions for unmet medical needs. Products everyone should have access to and that deliver a true benefit. As motivated physicians, researchers, and innovative leaders, it is our goal to make a difference in the lives of people everywhere by continuously improving and evaluating our goals and objectives to further the advancement of health care.
